Evidence map›Paper›PMID 41254130›Full record

ArticleNature biomedical engineering2026

Label-free navigation system for grading prostate tumour malignancy in situ via tissue pH and prostate-specific antigen activity.

Ziyi Jin, Sihui Chen, Xiaoyan Dong, Zheng Zhao, Huaiyang Zeng, Pengcheng Zhang, Hang Yin, Suhongrui Zhou, Changle Li, Chang He and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ziyi Jin *Department of Urology, Zhongshan Hospital, Fudan University; School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-3115-7225
Sihui Chen *State Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Xiaoyan Dong *Department of Urology, Zhongshan Hospital, Fudan University; School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai, China.
Zheng Zhao *College of Biomedical Engineering, Fudan University, Shanghai, China.
Huaiyang ZengState Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Pengcheng ZhangState Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Hang YinDepartment of Urology, Zhongshan Hospital, Fudan University; School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai, China.
Suhongrui ZhouDepartment of Urology, Zhongshan Hospital, Fudan University; School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai, China.
Changle LiState Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Chang HeMOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, State Key Laboratory of Brain Function and Disorders, Minhang Hospital, Xuhui Hospital, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Jiaqi HuangMOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, State Key Laboratory of Brain Function and Disorders, Minhang Hospital, Xuhui Hospital, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Jun ZhangMOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, State Key Laboratory of Brain Function and Disorders, Minhang Hospital, Xuhui Hospital, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Jie ChengMOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, State Key Laboratory of Brain Function and Disorders, Minhang Hospital, Xuhui Hospital, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Hairong ZhengState Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. hr.zheng@siat.ac.cn.ORCID http://orcid.org/0000-0002-8558-5102
Jinhua YuCollege of Biomedical Engineering, Fudan University, Shanghai, China. jhyu@fudan.edu.cn.ORCID http://orcid.org/0000-0002-0654-6034
Hui YangState Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. hui.yang@siat.ac.cn.ORCID http://orcid.org/0000-0002-6800-6308
Hang WangDepartment of Urology, Zhongshan Hospital, Fudan University; School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai, China. wang.hang@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-3301-2548
Cong LiDepartment of Urology, Zhongshan Hospital, Fudan University; School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai, China. congli@fudan.edu.cn.ORCID http://orcid.org/0000-0001-7731-8031

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82025019; 82227806; 92159304Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission) 23TS1401100; 23J21901700Shanghai Municipal Health Bureau (Shanghai Municipal Public Health Bureau) 2022JC003
6 · The paper itself

Abstract

Radical prostatectomy is a standard curative approach for high-risk prostate cancer, yet accurately defining tumour margins during surgery remains a major challenge. Intraoperative assessment of prostate tumour malignancy-particularly those with high aggressiveness catalogued in Gleason grade group (GG) ≥ 3-is crucial to prevent positive surgical margins and minimize postoperative complications. Here we develop a surface-enhanced Raman scattering (SERS)-based navigation system for intraoperative localization of high-grade malignant regions by simultaneously accessing tissue acidity and prostate-specific antigen (PSA) enzymatic activity. This system integrates a sampling pen for automated biomarker extraction from tissue surfaces, a nano-imprinted SERS array producing a ratiometric Raman signal in response to acidity and PSA activity, and a two-dimensional deep-learning model for rapid Raman spectral interpretation. We show that the system can intraoperatively identify GG ≥ 3 malignancies in fresh prostate tissues from 144 Chinese patients with an area under the receiver operating characteristic curve of 0.89. This SERS-based navigation system holds strong potential to enhance surgical precision, minimize tumour residue and ultimately improve patient outcomes.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsBiomarkers, TumorHumansHydrogen-Ion ConcentrationMaleNeoplasm GradingProstateProstatectomyROC CurveSpectrum Analysis, RamanBiomarkers, TumorProstate-Specific Antigen

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.